Business Wire · Mar 2026
Announcement of a collaboration with Rosebud, Kantify, and Incite to evaluate off-target chemotherapeutic toxicities in patient-specific heart, liver, and kidney organoids.
Growing micro-organs to find new drugs
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Rosebud Biosciences is a 2020 biotechnology startup building patient-specific hiPSC-derived organoid models for rare-disease drug discovery and toxicity screening. Public sources place it in the San Francisco Bay Area, though the exact HQ city is reported inconsistently across sources; the company appears to be a very small, B2B, partnership-driven platform business with a pre-seed round and an NSF SBIR Phase I grant.
Primary product
Patient-specific hiPSC-derived organoid platform for rare-disease drug discovery and toxicity screening
Founded
2020
Headquarters
San Carlos, California, United States / San Francisco Bay Area, California, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Organoid-based drug discovery and precision medicine
Open Positions
14 jobs at Rosebud Biosciences
Implementation Strategist
On-siteSales OpsCalifornia5mo ago
On-site